Administration of kit-ligand (KL) before and after doses of 5-fluorouracil (5-FU) results in marrow failure in mice, presumably because of enhanced KL-induced cycling of stem cells, which makes them more susceptible to the effects of 5-FU. In attempt to capitalize on this effect on stem cells, we studied the ability of KL and 5-FU to allow stable donor engraftment of congenically marked marrow in a C57BL/6 (B6) mouse model. KL was administered subcutaneously at 50 μg/kg, 21 hours and 9 hours before and 3 hours after each of two doses of 5-FU (125 mg/kg) given 7 days apart to B6-recipients. Animals then received three injections of 107 congenic B6-Gpi-1a-donor bone marrow cells at 24, 48, and 72 hours after the second 5-FU dose. A separate group of animals received a single dose of either 1 × 107 or 3 × 107 donor marrow cells 24 hours after the last 5-FU dose. The level of engraftment was measured from Gpi-phenotyping at 1, 3, 6, and 8 months in red blood cells (RBCs) and at 8 months by phenotyping cells from the thymus, spleen, and marrow. Percent donor engraftment in RBCs appeared stable after 6 months. The percent donor engraftment in RBCs at 8 months was significantly higher in KL + 5-FU prepared recipients (33.0 ± 2.7), compared with 5-FU alone (18.5 ± 2.6, P < .0005), or saline controls (17.8 ± 1.7, P < .0001). In an additional experiment, granulocyte colony-stimulating factor (100 μg/dose) was added to a reduced dose of KL (12.5 μg/dose); engraftment was similar to KL alone. At 8 months after transplantation the levels of engraftment in other tissues such as bone marrow, spleen, and thymus correlated well with erythroid engraftment to suggest that multipotent long-term repopulating stem cells had engrafted in these animals. There are concerns for the toxicity of total body irradiation (TBI)- or busulfan-based regimens in young recipients of syngeneic or transduced autologous marrow who are transplanted for correction of genetic disease. In these recipients complete donor engraftment may not be needed. The results with KL and 5-FU are encouraging for the further refinement of non-TBI, nonbusulfan techniques to achieve stable mixed chimerism.

THE PREPARATION of patients that undergo bone marrow transplantation (BMT) often involves total body irradiation (TBI) or busulfan-based regimens to provide for stem cell ablation, immune suppression, and, in case of leukemia, eradication of malignant cells. In addition to the deleterious effects of TBI and busulfan on hematopoietic stem cells, they can also be hazardous to nonhematologic tissues leading to unacceptable toxicities especially in young children. In experimental murine BMT, no drugs other than busulfan and derivatives have been found to allow long-term engraftment without unacceptable normal tissue side effects.1-3 However, correction of genetic hematologic disorders with syngeneic or transduced autologous cells may require only partial stem cell ablation and milder conditioning may thus suffice. In addition, preferential engraftment along the defected lineage as reported for genetically anemic W/Wv mice,4-6 thalassemic mice,7-9 and also in patients with genetic hematologic disorders10-13 have indicated a selective growth advantage of healthy stem cells into the defective lineage so that successful reconstitution may be achieved after partial stem cell ablation. To explore alternative conditioning protocols not including TBI or busulfan, we prepared recipients with a combination of 5-fluorouracil (5-FU) and kit-ligand (KL). KL exacerbates marrow failure if administered before 5-FU,14 suggesting that KL stimulates the cycling of hematopoietic cells making them more vulnerable to the effects of 5-FU. A second 5-FU dose given within 4 to 7 days after the first dose also appears to sensitize primitive stem cells as shown in a competitive repopulation assay.15 Therefore, a 2-week schedule where KL was administered in combination with 5-FU was evaluated as a preparative regimen for BMT.

The ligand for the c-kit receptor (KL) synergizes with other hematopoietic growth factors to induce proliferation of BM progenitors in vitro.16,17 Furthermore, KL has the ability to mobilize hematopoietic stem cells from the BM into the peripheral blood (PB), especially when given in combination with granulocyte colony-stimulating factor (G-CSF ).18-21 It also protects animals from lethal irradiation when given before irradiation,22-24 and KL enhances recovery from radiation-induced aplasia.25 Because KL has the ability to protect against lethal irradiation, it was expected that KL would also protect from 5-FU, a drug that preferentially kills cycling cells. However, recent reports show that the opposite is the case; KL added to 5-FU appears to increase damage to the hematopoietic progenitor pool.14 Similar results with the radioprotector interleukin-1 (IL-1) have also been reported.26 These reports only described effects on committed progenitors in short-term assays, such as 30-day survival and colony-forming unit-spleen (CFU-S) frequencies. Therefore, we measured the effects on the more primitive long-term repopulating ability (LTRA)-subset with the cobblestone area forming cell (CAFC)-assay and in a competitive repopulation assay. Finally, we compared LTRA-survival after several variations on the KL/5-FU combination protocol with the ability of these protocols to allow for permanent long-term engraftment.

Mice and treatment.C57BL/6J (B6) mice and C57BL/6J-CAST-Gpi-1a/Gpi-1a (B6-Gpi-1a) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Male C57BL/6J (B6) mice were used as recipients and B6-Gpi-1a mice as donors. Recipient mice were prepared by subcutaneous administration of KL (50 μg/kg/injection at −21, −9, and +3 hours relative to 5-FU [125 mg/kg] given intravenously) in 2 consecutive weeks according to the design shown in Fig 1. In some experiments G-CSF (100 μg/kg/injection) was combined with KL given at a lower dosage (12.5 μg/kg/injection). KL and G-CSF were generously provided by Amgen Inc (Thousand Oaks, CA).

Fig. 1.

Design of conditioning with 5-FU and KL. Recipient mice were prepared by administration of KL (50 μg/kg/injection at −21, −9, and +3 hours relative to 5-FU (125 mg/kg)) in 2 consecutive weeks. Ten million donor BM cells were injected into the tail vein at 24, 48, and 72 hours after the last 5-FU injection. See Materials and Methods for more detailed explanation.

Fig. 1.

Design of conditioning with 5-FU and KL. Recipient mice were prepared by administration of KL (50 μg/kg/injection at −21, −9, and +3 hours relative to 5-FU (125 mg/kg)) in 2 consecutive weeks. Ten million donor BM cells were injected into the tail vein at 24, 48, and 72 hours after the last 5-FU injection. See Materials and Methods for more detailed explanation.

Close modal

BM from B6-Gpi-1a donors was collected by flushing the hind limbs with sterile phosphate-buffered saline (PBS). Single-cell suspensions were obtained and nucleated cells were counted in Trypan Blue on a hemocytometer. Ten million viable cells were injected into the tail vein at 24, 48, and 72 hours after the last 5-FU injection. This procedure was used since it was shown that large daily doses of BM cells could optimize engraftment in unconditioned animals.27 Separate groups of animals received only one injection of either 1 × 107 or 3 × 107 donor marrow cells at 24 hours after the second dose of 5-FU.

Recipients were bled 1, 3, and 6 months after BMT and ratios of donor (Gpi-1a) to recipient type (Gpi-1b) red blood cells were determined by Gpi-electrophoresis as described.28 At 8 months after BMT mice were killed and the level of engraftment in other hematopoietic tissues such as BM, spleen, and thymus was compared with engraftment in erythrocytes.

Competitive repopulation of treated BM.In the competitive repopulation assay the long-term repopulating ability of a stem cell population relative to normal BM cells is measured. Briefly, varying numbers of BM cells from 5-FU– and KL-treated B6 (Gpi-1b) mice were mixed with a constant number (5 × 105) of normal control (B6-Gpi-1a) marrow cells. The mixtures were then injected into lethally irradiated (1,250 cGy split-dose TBI; 750 and 500 cGy 3 hours apart) B6 recipients. Endogenous marrow repopulation was determined by injecting a group of mice with control Gpi-1a cells only and was found to be less than 5% (4.1 ± 2.4). Recipients were killed at 6 months after BMT and ratios of test (Gpi-1b) to control (Gpi-1a) cells determined by electrophoresis of BM cell extracts. A measure of long-term repopulating cells, the repopulating unit, was calculated according to the formula:

RU=(%of Gpi­1b*C)/(100­%of Gpi­1b)

where C is the number of RU in control (Gpi-1a) marrow and 1 RU is defined as the repopulating ability of 105 normal BM cells.29 

CAFC assay of treated BM.BM cells treated according to the schedule were collected at 24 hours after the second 5-FU injection and assayed in a CAFC-assay.30-32 Each hind limb was carefully dissected, crushed, and filtered through a metal sieve to obtain a single BM cell suspension in PBS. The cell yield was determined by counting cells in a hematocytometer and then the cells were diluted in Iscove's medium (GIBCO-BRL, Gaithersburg, MD) supplemented with 20% horse serum, 100 U penicillin/mL, 0.1 mg streptomycin/mL, 10−5 mol/L hydrocortisone, and 10−5 mol/L 2-mercaptoethanol before overlaying the cells on a preestablished stromal layer of FBMD-1 stromal cells (generously provided by Dr Steve Neben, Genetics Institute, Cambridge, MA). In each treatment group 8 dilutions with 15 wells per dilution were used. The cells were maintained at 33°C and 5% CO2 . Half of the medium (100 μL) was replaced weekly. Wells were evaluated for cobblestone areas at day 7, day 14, day 21, day 28, and day 35. CAFC frequencies were calculated as described.32,33 

Engraftment after conditioning with 5-FU and KL.Pretreatment of mice with KL and 5-FU allowed for engraftment of syngeneic (congenically marked) BM. Figure 2 shows that the level of engraftment was more than 50% at 1 month after BMT and stabilized at 30% to 40% between 6 and 8 months in the groups where KL was included in the 2-week conditioning protocol. Engraftment with 5-FU and KL was significantly higher than saline (P < .0001) and 5-FU alone (P < .002). When only 5-FU was administered the percentage chimerism dropped from about 40% at 1 month to 19% at 8 months post-BMT, similar to the saline control group (18% at 8 months). Table 1 shows the level of engraftment evaluating several alternative conditioning regimens including 5-FU with or without either the normal or a reduced dose of KL, and 1-week cycles versus 2-week cycles. Among animals receiving 3 × 107 cells and only a single dose of 5-FU with KL, engraftment at 6 to 8 months was not different from saline or 5-FU alone (P = .11 and P = .79, respectively), supporting the efficacy of two sequential (weekly) doses of 5-FU with KL. With a fourfold reduction in KL dose combined with two doses of 5-FU, the level of engraftment at 8 months was not different from 5-FU alone or saline, demonstrating a dose-response effect for KL. However, G-CSF added to this reduced dose had the effect of increasing engraftment to about 60% at 1 month after BMT and about 30% at 8 months post-BMT (P = .004 v saline; P = .01 v 5-FU; P = .01 v 5-FU/KL [low dose] and P = .43 v 5-FU/KL [normal dose]), suggesting that the addition of G-CSF to lower doses of KL could provide the same level of engraftment as the normal dose of KL.

Fig. 2.

Development of chimerism after conditioning with 5-FU and KL. Recipients prepared with two weekly doses of saline, 5-FU, 5-FU + KL, 5-FU + KL (low dose), or 5-FU + KL (low dose) + G-CSF were transplanted with 3 × 107 BM cells divided over 3 consecutive days (24, 48, and 72 hours after the last 5-FU injection). The level of chimerism was determined at various times after BMT by Gpi-phenotyping of PB erythrocytes.

Fig. 2.

Development of chimerism after conditioning with 5-FU and KL. Recipients prepared with two weekly doses of saline, 5-FU, 5-FU + KL, 5-FU + KL (low dose), or 5-FU + KL (low dose) + G-CSF were transplanted with 3 × 107 BM cells divided over 3 consecutive days (24, 48, and 72 hours after the last 5-FU injection). The level of chimerism was determined at various times after BMT by Gpi-phenotyping of PB erythrocytes.

Close modal
Table 1.

Engraftment After 5-FU/KL Ablation

TreatmentNo. of Weekly Cycles% Gpi-1a Engraftment (PB)
1 mo3 mo6 mo8 mo
Three injections of 107 BM cells: 
   
Saline 3.4 ± 0.9 (15) 12.6 ± 0.9 (14) 12.4 ± 2.1 (15) 17.8 ± 1.7 (15) 
5-FU 26.7 ± 2.5 (5) 10.9 ± 2.1 (5) 14.4 ± 1.7 (5) 15.0 ± 1.5 (5) 
5-FU 44.8 ± 3.3 (13) 27.1 ± 4.8 (12) 17.7 ± 3.0 (15) 18.5 ± 2.6 (15) 
5-FU + KL* 39.0 ± 3.4 (10) 20.2 ± 2.1 (10) 16.8 ± 1.6 (10) 13.5 ± 1.0 (10) 
5-FU + KL (12.5 μg/kg) 38.1 ± 5.6 (10) 22.7 ± 6.2 (10) 21.8 ± 2.1 (10) 19.7 ± 2.1 (10) 
5-FU + KL* 55.0 ± 3.2 (18) 39.9 ± 4.4 (18) 32.3 ± 2.9 (18) 33.0 ± 2.7 (18) 
5-FU + KL + G-CSF 57.8 ± 2.5 (9) 40.7 ± 2.3 (9) 28.2 ± 2.8 (9) 29.7 ± 3.0 (9) 
One injection of 107 BM cells: 
   
5-FU 17.7 ± 1.9 (5) 5.4 ± 1.0 (5) 12.2 ± 0.6 (5) 6.5 ± 0.6 (5) 
5-FU 21.6 ± 2.4 (5) 2.2 ± 1.7 (5) 9.6 ± 1.4 (5) 9.8 ± 1.2 (5) 
5-FU + KL* 46.2 ± 3.9 (10) 22.7 ± 3.9 (10) 21.6 ± 2.9 (10) 15.0 ± 2.5 (10) 
One injection of 3 × 107 BM cells: 
   
5-FU + KL* 60.2 ± 1.3 (5) 51.2 ± 3.0 (5) 28.6 ± 3.9 (5) 30.5 ± 1.5 (5) 
TreatmentNo. of Weekly Cycles% Gpi-1a Engraftment (PB)
1 mo3 mo6 mo8 mo
Three injections of 107 BM cells: 
   
Saline 3.4 ± 0.9 (15) 12.6 ± 0.9 (14) 12.4 ± 2.1 (15) 17.8 ± 1.7 (15) 
5-FU 26.7 ± 2.5 (5) 10.9 ± 2.1 (5) 14.4 ± 1.7 (5) 15.0 ± 1.5 (5) 
5-FU 44.8 ± 3.3 (13) 27.1 ± 4.8 (12) 17.7 ± 3.0 (15) 18.5 ± 2.6 (15) 
5-FU + KL* 39.0 ± 3.4 (10) 20.2 ± 2.1 (10) 16.8 ± 1.6 (10) 13.5 ± 1.0 (10) 
5-FU + KL (12.5 μg/kg) 38.1 ± 5.6 (10) 22.7 ± 6.2 (10) 21.8 ± 2.1 (10) 19.7 ± 2.1 (10) 
5-FU + KL* 55.0 ± 3.2 (18) 39.9 ± 4.4 (18) 32.3 ± 2.9 (18) 33.0 ± 2.7 (18) 
5-FU + KL + G-CSF 57.8 ± 2.5 (9) 40.7 ± 2.3 (9) 28.2 ± 2.8 (9) 29.7 ± 3.0 (9) 
One injection of 107 BM cells: 
   
5-FU 17.7 ± 1.9 (5) 5.4 ± 1.0 (5) 12.2 ± 0.6 (5) 6.5 ± 0.6 (5) 
5-FU 21.6 ± 2.4 (5) 2.2 ± 1.7 (5) 9.6 ± 1.4 (5) 9.8 ± 1.2 (5) 
5-FU + KL* 46.2 ± 3.9 (10) 22.7 ± 3.9 (10) 21.6 ± 2.9 (10) 15.0 ± 2.5 (10) 
One injection of 3 × 107 BM cells: 
   
5-FU + KL* 60.2 ± 1.3 (5) 51.2 ± 3.0 (5) 28.6 ± 3.9 (5) 30.5 ± 1.5 (5) 
*

KL = 50 μg/kg/dose.

KL = 12.5 μg/kg/dose; G-CSF = 100 μg/kg/dose.

Mean ± SEM (n).

A single dose of 1 × 107 BM cells at 24 hours after 5-FU + KL (2 cycles) resulted in about 15% engraftment at 8 months (P < .0001 v three injections). An increase in the number of BM cells to 3 × 107 given in one single injection at 24 hours after 5-FU + KL (2 cycles) led to a level of engraftment comparable to three separate injections of 1 × 107 BM cells on three consecutive days after 5-FU + KL (P = .46), suggesting that the number of transplanted cells and not the number of injections influenced engraftment. Thus, the factors most important for the percentage of chimerism are the use of 2 cycles of 5-FU + KL, the dose of KL, and the number of cells transplanted.

Figure 3 shows the levels of engraftment in erythrocytes, BM cells, spleen cells, and thymocytes at 8 months after BMT in various treatment groups. The level of chimerism in the different hematopoietic tissues is comparable within each group, suggesting stable and permanent engraftment of long-term repopulating cells with multilineage differentiation potential. Other groups also had comparable levels of engraftment in all hematopoietic tissues at 8 months after BMT (data not shown).

Fig. 3.

Correlation between erythroid chimerism and chimerism in BM, spleen, and thymus. Recipients prepared with two weekly doses of saline, 5-FU, 5-FU + KL, 5-FU + KL (low dose), or 5-FU + KL (low dose) + G-CSF were transplanted with 3 × 107 BM cells divided over 3 consecutive days (24, 48, and 72 hours after the last 5-FU injection). The level of chimerism was determined at 8 months after BMT by Gpi-phenotyping of erythrocytes, BM cells, splenocytes, and thymocytes.

Fig. 3.

Correlation between erythroid chimerism and chimerism in BM, spleen, and thymus. Recipients prepared with two weekly doses of saline, 5-FU, 5-FU + KL, 5-FU + KL (low dose), or 5-FU + KL (low dose) + G-CSF were transplanted with 3 × 107 BM cells divided over 3 consecutive days (24, 48, and 72 hours after the last 5-FU injection). The level of chimerism was determined at 8 months after BMT by Gpi-phenotyping of erythrocytes, BM cells, splenocytes, and thymocytes.

Close modal

Competitive repopulation of treated BM.BM cells treated according to the schedule mentioned in Materials and Methods were collected at 24 hours after the second 5-FU injection and assayed in a competitive repopulation assay. Because the cell loss after treatment is considerable, it is preferable to express competitive repopulation as repopulating units (RU) per hind limb. Table 2 shows that 5-FU alone depleted the RU to 84% of normal, but the combination of KL and 5-FU depleted the RU to 16% of normal. Combining G-CSF with a reduced dose of KL had a comparable effect on the number of surviving RU.

Table 2.

Survival of LTRA 24 Hours After 5-FU and KL as Measured in the Competitive Repopulation Assay

TreatmentNo. of Weekly CyclesRU/Hind Limb% of Control
Saline 127 100 
5-FU alone 106 84 
5-FU + KL 20 16 
5-FU + KL + G-CSF 17 14 
TreatmentNo. of Weekly CyclesRU/Hind Limb% of Control
Saline 127 100 
5-FU alone 106 84 
5-FU + KL 20 16 
5-FU + KL + G-CSF 17 14 

Repopulation units were calculated from chimerism in lethally irradiated recipients at 8 months after transplantation of BM cells from treated BM mixed with a constant number of untreated BM. The repopulation units (RU) were calculated according to the formula: RU = (% of Gpi-1b * C)/(100-% of Gpi-1b), where C is the number of RU in control (Gpi-1a) marrow and 1 RU is defined as the repopulating ability of 105 normal BM cells.29 

CAFC assay of treated BM.In addition to the competitive repopulation in vivo, treated BM cells were tested in vitro in the CAFC assay. Figure 4 shows survival of CAFC after 5-FU or 5-FU combined with KL. The data are presented as the number of CAFC per hind limb (Fig 4A) and as a percentage of control, saline-treated marrow (Fig 4B). The data are presented in more detail in Table 3. It can be seen that protocols with two cycles of 5-FU + KL (high dose) or 5-FU + KL (low dose) + G-CSF have a dramatic effect on early CAFC (CAFC-7), the subset that correlates with progenitors such as CFU-S day 8,31 leading to a level of survival of only 0.03% to 0.06%. Survival of late CAFC (CAFC-28/CAFC-35; similar to long-term repopulating stem cells) was 10% to 16%, comparable to the level of survival of primitive stem cells measured in the competitive repopulation assay. In contrast, 2 cycles of 5-FU without KL resulted in 4% and 49% survival of CAFC-7 and CAFC-28, respectively. Table 3 shows the results of other treatments with 5-FU with or without KL on CAFC-survival. One dose of 5-FU did not significantly reduce CAFC-28 numbers where two doses of 5-FU 7 days apart reduced CAFC-28 numbers to about 50% of control (P < .05 v saline). There was no significant additional CAFC-28 depletion when one dose of 5-FU was combined with KL.

Fig. 4.

CAFC-survival after conditioning with 5-FU and KL. Mice (2 to 3 per group) were treated with two weekly doses of saline, 5-FU, or 5-FU + KL, and killed 24 hours after the last 5-FU dose to test CAFC-survival. (A) Residual CAFC per hind limb; (B) the percentage of surviving CAFC relative to control (saline treated) both as a function of CAFC-day type. Early CAFC (day 7) correlate with committed progenitors like CFU-S day 8 and late CAFC (day 28 and later correlate with long-term repopulating stem cells (LTRA).31 (▪), control marrow; (♦), 5-FU marrow; (•), 5-FU + KL.

Fig. 4.

CAFC-survival after conditioning with 5-FU and KL. Mice (2 to 3 per group) were treated with two weekly doses of saline, 5-FU, or 5-FU + KL, and killed 24 hours after the last 5-FU dose to test CAFC-survival. (A) Residual CAFC per hind limb; (B) the percentage of surviving CAFC relative to control (saline treated) both as a function of CAFC-day type. Early CAFC (day 7) correlate with committed progenitors like CFU-S day 8 and late CAFC (day 28 and later correlate with long-term repopulating stem cells (LTRA).31 (▪), control marrow; (♦), 5-FU marrow; (•), 5-FU + KL.

Close modal
Table 3.

CAFC Survival 24 Hours After 5-FU/KL Ablation

TreatmentNo. of Weekly CyclesCAFC Survival
CAFC-7/HL(%)CAFC-28/HL(%)
Saline 81,592 (61,131-108,901)ρ 100 1,939 (1,427-2,634) 100 
5-FU 2,258 (1,540-3,309) 2.8 (1.9-4.1) 1,164 (797-1,699) 60 (41-88) 
5-FU 2,827 (2,158-3,702) 3.5 (2.6-4.5) 952 (715-1,266) 49 (37-65) 
5-FU + KL3-150 2,116 (1,433-3,126) 2.6 (1.8-3.8) 885 (557-1,408) 45.6 (28.7-72.6) 
5-FU + KL3-151  127 (87-187) 0.16 (0.11-0.23) 263 (179-385) 13.6 (9.2-19.9) 
5-FU + KL3-150  51 (39-66) 0.06 (0.05-0.08) 192 (148-250) 9.9 (7.6-12.9) 
5-FU + KL + G-CSF3-152 23.4 (13.0-42.1) 0.03 (0.02-0.05) 319 (217-467) 16.4 (11.2-24.1) 
TreatmentNo. of Weekly CyclesCAFC Survival
CAFC-7/HL(%)CAFC-28/HL(%)
Saline 81,592 (61,131-108,901)ρ 100 1,939 (1,427-2,634) 100 
5-FU 2,258 (1,540-3,309) 2.8 (1.9-4.1) 1,164 (797-1,699) 60 (41-88) 
5-FU 2,827 (2,158-3,702) 3.5 (2.6-4.5) 952 (715-1,266) 49 (37-65) 
5-FU + KL3-150 2,116 (1,433-3,126) 2.6 (1.8-3.8) 885 (557-1,408) 45.6 (28.7-72.6) 
5-FU + KL3-151  127 (87-187) 0.16 (0.11-0.23) 263 (179-385) 13.6 (9.2-19.9) 
5-FU + KL3-150  51 (39-66) 0.06 (0.05-0.08) 192 (148-250) 9.9 (7.6-12.9) 
5-FU + KL + G-CSF3-152 23.4 (13.0-42.1) 0.03 (0.02-0.05) 319 (217-467) 16.4 (11.2-24.1) 
F3-150

KL = 50 μg/kg/dose.

F3-151

KL = 12.5 μg/kg/dose.

F3-152

KL = 12.5 μg/kg/dose; G-CSF = 100 μg/kg/dose.

ρ Mean with 95% confidence interval range in parentheses.

Comparison of engraftment, RU, and CAFC depletion.All 2-week schedules with KL (50 μg/kg/dose, 12.5 μg/kg/dose, and 12.5 μg/kg/dose + G-CSF ) were effective in depleting CAFC-28 numbers to below 20%. 5-FU + KL and 5-FU + KL + G-CSF also resulted in depletion of repopulating units to less than 20%. These were also the schedules that led to the highest levels of engraftment after BMT of 3 × 107 donor marrow cells (Fig 5). These data show a correlation between the number of residual host primitive stem cells and the level of long-term donor engraftment.

Fig. 5.

The relationship between CAFC-survival and donor engraftment. The percentage of donor engraftment is shown as a function of the residual CAFC per hind limb. The treatment groups are divided into effective (2-week protocols with KL; 5-FU + KL [high dose], 5-FU + KL [low dose], 5-FU + KL [low dose] + G-CSF ) and noneffective (saline, 5-FU alone [1-week and 2-week], 5-FU + KL [1-week]) protocols based on engraftment data in Table 1.

Fig. 5.

The relationship between CAFC-survival and donor engraftment. The percentage of donor engraftment is shown as a function of the residual CAFC per hind limb. The treatment groups are divided into effective (2-week protocols with KL; 5-FU + KL [high dose], 5-FU + KL [low dose], 5-FU + KL [low dose] + G-CSF ) and noneffective (saline, 5-FU alone [1-week and 2-week], 5-FU + KL [1-week]) protocols based on engraftment data in Table 1.

Close modal

The data presented in this report show that administration of KL before and after 5-FU leads to stable donor engraftment after transplantation. The correlation between erythroid engraftment and engraftment in other tissues such as BM, spleen, and thymus at 8 months after transplantation suggests that multipotent long-term repopulating stem cells engrafted in these animals. Thus, permanent long-term engraftment can be obtained through cytokine induced stimulation of stem cells into cycle and subsequent killing by 5-FU. This long-term engraftment is stable and can be achieved without the use of TBI or busulfan-related regimens.

It has been reported that BM cells are stimulated when cultured in the presence of cytokines. KL has been shown to synergize with erythropoietin, IL-3, IL-6, IL-12, G-CSF, and granulocyte-macrophage (GM)-CSF to increase the size and numbers of erythroid, granuloid, and macrophage colonies derived from murine16,34,35 or human BM.17,36,37 However, in vitro expansion of BM cells may result in impaired long-term engraftment potential and it therefore remains doubtful whether the most primitive stem cells are expanded in these cultures.38,39 A recent study showed that cytokines such as KL and IL-11 are critical for survival and maintenance of primitive stem cells in culture, but expansion occurs only among the more committed progenitor cell population.40 KL also induces a migration of colony-forming progenitors and long-term repopulating stem cells from the marrow to the spleen and to the PB.18-21 Thus, KL is a very potent stimulator of hematopoiesis at many different levels of differentiation.

G-CSF is often used to accelerate hematopoietic recovery after chemotherapy or radiotherapy41 and has also been shown to be a potent mobilization agent.18,42 The mobilizing effect of KL and the synergy between KL and G-CSF in mobilizing stem cells from the marrow to the PB is probably caused by an increased proliferation of stem cells.43,44 We tried to capitalize on the increased in vivo proliferation of stem cells by using both these agents in combination with 5-FU to prepare the host for BMT. Clinically, KL can be toxic and an effective alternative regimen using lower doses of KL in combination with other cytokines such as G-CSF may make its use more feasible in the clinic.

5-FU is often used experimentally as a pre-enrichment step to purify murine BM stem cells because it preferentially kills cycling cells. Following 5-FU treatment, the number of LTRA per 106 cells increases, but the total number of LTRA per femur does not change significantly.30,45 Thus, the main effect of 5-FU is depletion of proliferating progenitors leading to reduced BM cellularity and this enriches for LTRA.46-48 Others have reported that when a single treatment with 5-FU is administered 24 hours before transplantation of 107 BM cells, very little engraftment is found (3.5%), presumably due to the lack of depletion of the primitive stem cell compartment.45 This result is in agreement with the 6.5% engraftment at 8 months after BMT of 107 cells following one dose of 5-FU reported in this paper.

Evidence was found for a cell dose effect on engraftment, since after similar conditioning, engraftment was higher with a total of 3 × 107 cells than after transplantation of 1 × 107 cells (eg, after two doses of 5-FU, 8-month engraftment was 18.5% with 3 × 107 cells and only 9.8% after 1 × 107 cells). In addition, an interesting difference between 5-FU– and saline-treated animals was observed after BMT of 3 × 107 cells. In 5-FU–treated animals we found an early engraftment of 45%, but this decreased to about 18.5% engraftment at 8 months after BMT. In saline-treated animals, the level of early engraftment was 3.4%; this increased to 17.8% at 8 months, a level comparable to the 5-FU–treated mice. Thus, a dose of 3 × 107 cells appears to result in modest engraftment of primitive stem cells even without conditioning, which in saline-treated mice gradually compete with the endogenous marrow stem cells to result in a low but substantial level of engraftment by 8 months. Two doses of 5-FU depleted the progenitor pool, probably allowing engraftment of transplanted committed progenitors which were eventually lost, leaving the same level of engrafted primitive stem cells (from the large number of donor cells transplanted) as in the saline controls. Therefore, 5-FU alone did not appear to enhance engraftment of primitive stem cells over control animals.

In a previous study, Harrison and Lerner15 reported a reduced long-term repopulation ability of BM after two doses of 5-FU administered 3, 5, or 8 days apart. They used a slightly higher 5-FU dose (150 mg/kg v 125 mg/kg) and found that at 8 days the second 5-FU dose was less effective than when the second dose was given at 3 or 5 days after the first dose. The addition of KL to a protocol with two treatments with 5-FU may change the turnover of LTRA and it therefore requires further investigation to see whether reducing the time between two 5-FU/KL cycles to 3 or 5 days will lead to more stem cell kill to allow for a higher level of long-term engraftment.

Engraftment in the first 3 months after BMT has been ascribed to stem cell subsets residing in the CFU-S compartment as shown from BM separation experiments.45,49,50 However, permanent, durable engraftment requires growth and differentiation of stem cells with LTRA.45,49,50 Preparative regimens that do not deplete host LTRA do not appear to be able to induce significant engraftment of donor LTRA unless very high numbers of BM cells are transplanted.27,51-53 In this study, the 5-FU alone and 5-FU + KL 1-week protocol showed no significant depletion of late CAFC (day 28 or 35) and engraftment after BMT of 3 × 107 cells was therefore not different from saline controls. On the other hand, conditioning of transplantation recipients with 2-week protocols including 5-FU and KL leads to a 80% to 90% depletion of both RU and late CAFC (CAFC-28 and 35) and subsequent engraftment of donor LTRA as demonstrated by 8-month multilineage donor engraftment. The combination of 5-FU and KL also showed an enhanced killing of the early CAFC-7 subset to indicate that KL induced more of these cells into cycle making them more susceptible to 5-FU. The eradication of this stem cell subset is lethal to mice without a BMT.14 The preferential ablation of rapidly dividing cells (more kill of early CAFC [day 7] than of late CAFC [day 28]) may cause side effects on other tissues with rapidly dividing cells such as skin and gut14 which need to be further investigated.

The reduced dose of KL in a 2-week protocol was almost as effective as the normal dose on CAFC-survival, but engraftment levels were not as high. However, when G-CSF was added to this reduced dose similar engraftment levels were reached as the normal dose of KL with 5-FU. The most likely explanation for these results is that one cycle of 5-FU and KL is not effective in depleting LTRA (no significant CAFC-28 killing and engraftment not higher than in saline controls), but induces LTRA to go into cycle, and this makes them more vulnerable to the second cycle of 5-FU and KL. The survival of LTRA is then reduced to 10% to 20%, which allows for long-term engraftment. Although the high BM cell dose of 3 × 107 led to a considerably higher level of engraftment than 1 × 107, 5-FU and KL also induced higher engraftment levels than 5-FU alone when only 1 × 107 were used.

The results with KL and 5-FU are encouraging for the further refinement of non-TBI, nonbusulfan techniques to achieve stable mixed donor-recipient chimerism. Because low levels of engraftment may be sufficient for phenotypic correction of genetic hematopoietic disorders such as thalassemia or chronic granulomatous disease,7,54 the use of alternative regimens with less toxicity than TBI or busulfan should be encouraged if they result in sufficient levels of stable donor chimerism. These techniques may be particularly useful for transplantation of transduced autologous stem cells when options of repeated stem cell infusions following minimally toxic regimens are feasible.

Supported by National Institutes of Health (NIH) RO1 Grant-CA 10941 and NIH P50 Grant-HL54785-01.

Address reprint requests to Ronald van Os, PhD, Joint Center for Radiation Therapy, Department of Radiation Oncology, Harvard Medical School, 330 Brookline Ave, Boston, MA 02215.

1
Mauch
P
Down
J
Warhol
M
Hellman
S
Recipient preparation for bone marrow transplantation. I. Efficacy of total-body irradiation and busulfan.
Transplantation
46
1988
205
2
Down
J
Berman
A
Warhol
M
Yeap
B
Mauch
P
Late tissue-specific toxicity of total body irradiation and busulfan in a murine bone marrow transplant model.
Int J Radiat Oncol Biol Phys
17
1989
109
3
Down
J
Boudewijn
A
Dillingh
J
Fox
B
Ploemacher
R
Relationship between ablation of distinct haematopoietic cell subsets and the development of donor bone marrow engraftment following recipient pretreatment with different alkylating drugs.
Br J Cancer
70
1994
611
4
Barker
J
Braun
J
McFarland-Starr
E
Erythrocyte replacement precedes leukocyte replacement during repopulation of W/WV mice with limiting dilutions of +/+ donor marrow cells.
Proc Natl Acad Sci USA
85
1988
7332
5
Nakano
T
Waki
N
Asai
H
Kitamura
Y
Lymphoid differentiation of the hematopoietic stem cell that reconstitutes total erythropoiesis of a genetically anemic W/WV mouse.
Blood
73
1989
1175
6
Nakano
T
Waki
N
Asai
H
Kitamura
Y
Different repopulation profile between erythroid and nonerythroid progenitor cells in genetically anemic W/WV mice after bone marrow transplantation.
Blood
74
1989
1552
7
Barker
J
Compton
S
Hematopoietic repopulation of adult mice with β-thalassemia.
Blood
83
1994
828
8
van den Bos
C
Kieboom
D
van der Sluijs
J
Baert
M
Ploemacher
R
Wagemaker
G
Selective advantage of normal erythrocyte production after bone marrow transplantation of A-thalassemic mice.
Exp Hematol
22
1994
441
9
van der Loo
J
van den Bos
C
Baert
M
Wagemaker
G
Ploemacher
R
Stable multilineage hematopoietic chimerism in A-thalassemic mice induced by a bone marrow subpopulation that excludes the majority of of day-12 spleen colony-forming units.
Blood
83
1994
1769
10
Parkman
R
Gelfand
E
Rosen
F
Sanderson
A
Hirschhorn
R
Severe combined immunodeficiency and adenosine deaminase deficiency.
N Engl J Med
292
1975
714
11
Ginsburg
D
Antin
J
Smith
B
Orkin
S
Rappeport
J
Origin of cell populations after bone marrow transplantation. Analysis using DNA sequence polymorphisms.
J Clin Invest
75
1985
596
12
Borzy
M
Ridgway
D
Noya
F
Shearer
W
Successful bone marrow transplantation with split lymphoid chimerism in DiGeorge syndrome.
J Clin Immunol
9
1989
386
13
Buckley R, Schiff S, Schiff R, Roberts J, Markert M, Peters W, Williams L, Ward F: Haploidentical bone marrow stem cell transplantation in human severe combined immunodeficiency. Semin Hematol 30:92, 1993 (suppl 4)
14
Molineux
G
Migdalska
A
Haley
J
Evans
G
Dexter
T
Total marrow failure induced by pegylated stem cell factor administered before 5-fluorouracil.
Blood
83
1994
3491
15
Harrison
D
Lerner
C
Most primitive hematopoietic stem cells are stimulated to cycle rapidly after treatment with 5-fluorouracil.
Blood
78
1991
1237
16
Broxmeyer
H
Hangoc
G
Cooper
S
Anderson
D
Cosman
D
Lyman
S
Williams
D
Influence of murine mast cell growth factor (c-kit ligand) on colony formation by mouse marrow hematopoietic progenitor cells.
Exp Hematol
19
1991
143
17
Hoffman R, Tong J, Brandt J, Traycoff C, Bruno E, McGuire B, Gordon M, McNiece I, Srour E: The in vitro and in vivo effects of Stem cell factor on human hematopoiesis. Stem Cells 11:76, 1993 (suppl 2)
18
Molineux
G
Migdalska
A
Szmitkowski
M
Zsebo
K
Dexter
T
The effects on hematopoiesis of recombinant stem cell factor (ligand for c-kit) administered in vivo to mice either alone or in combination with granulocyte colony-stimulationg factor.
Blood
78
1991
961
19
Andrews
R
Bensinger
W
Knitter
G
Bartelmez
S
Longin
K
Bernstein
I
Applebaum
F
Zsebo
K
The ligand for c-kit, stem cell factor, stimulates the circulation of cells that engraft lethally irradiated baboons.
Blood
80
1992
2715
20
Briddell
R
Hartley
C
Smith
K
McNiece
I
Recombinant rat stem cell factor syngergizes with recombinant human granulocyte colony-stimulating factor in vivo in mice to mobilize peripheral blood and progenitor cells that have enhanced repopulating potential.
Blood
82
1993
1720
21
Mauch
PM
Lamont
C
Neben
TY
Quinto
C
Goldman
SJ
Witsell
A
Hematopoietic stem cells in the blood following stem cell factor and IL-11: Evidence for different mechanisms of mobilization.
Blood
86
1995
4674
22
Zsebo
K
Smith
K
Hartley
C
Greenblatt
M
Cooke
K
Rich
W
McNiece
I
Radioprotection of mice by recombinant rat stem cell factor.
Proc Natl Acad Sci USA
89
1992
9464
23
Neta
R
Oppenheim
J
Wang
J-M
Snapper
C
Moorman
M
Dubois
C
Synergy of IL-1 and stem cell factor in radioprotection of mice is associated with IL-1 up-regulation of mRNA and protein expression for c-kit on bone marrow cells.
J Immunol
153
1994
1536
24
Van Os R, Lamont C, Witsell A, Mauch P: Radioprotection of bone marrow stem cell subsets by interleukin-1 and Kit-ligand: Implications for CFU-S as the responsible target cell population. Exp Hematol 1997 (in press)
25
Patchen
M
Fisher
R
Schmauder-Chock
E
Williams
D
Mast cell growth factor enhances multilineage hematopoietic recovery in vivo following radiation-induced aplasia.
Exp Hematol
22
1994
31
26
Neta
R
Keller
J
Ali
N
Blanchette
F
Dubois
C
Contrasting mechanisms of the myeloprotective effects of Interleukin-1 against ionizing radiation and cytotoxic 5-fluorouracil.
Radiat Res
145
1996
624
27
Stewart
F
Crittenden
R
Lowry
P
Pearson-White
S
Quesenberry
P
Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice.
Blood
81
1993
2566
28
Ansell J, Micklem H: Genetic markers for following cell populations, in Weir DM, Herzenberg LA, Blackwell CC (eds): Handbook of Experimental Immunology, vol 2 (ed 4). Edinburgh, UK, Blackwell, 1986, p 56.1
29
Harrison
D
Jordan
C
Zhong
R-K
Astle
C
Primitive hemopoietic stem cells: Direct assay of most productive populations by competitive repopulation with simple binomial, correlation and covariance calculations.
Exp Hematol
21
1993
206
30
Ploemacher
R
van der Sluijs
J
Voerman
J
Brons
N
An in vitro limiting-dilution assay of long-term repopulating hematopoietic stem cells in the mouse.
Blood
74
1989
2755
31
Neben
S
Anklesaria
P
Greenberger
J
Mauch
P
Quantitation of murine hematopoietic stem cells in vitro by limiting dilution analysis of cobblestone area formation on a cloned stromal cell line.
Exp Hematol
21
1993
438
32
Ploemacher R: Cobblestone area forming cell (CAFC) Assay, in Freshney RI, Pragnell IB, Freshney MG (eds): Culture of Hemopoietic Cells. New York, NY, Wiley-Liss, 1994, p 1
33
Fazekas de st. Groth S: The evaluation of limiting dilution assays. J Immunol Meth 49:R11, 1982
34
Ploemacher
R
van Soest
P
Boudewijn
A
Neben
S
Interleukin-12 enhances interleukin-3 dependent multilineage hematopoietic colony formation stimulated by interleukin-11 and Steel factor.
Leukemia
7
1993
1374
35
Wu
D
Nayar
R
Keating
A
Synergistic effect of stem cell factor with interleukin-3 or granulocyte-macrophage colony-stimulating factor on the proliferation of murine primitive hematopoietic progenitors.
Exp Hematol
22
1994
495
36
Broxmeyer
HE
Cooper
S
Lu
L
Hangoc
G
Anderson
D
Cosman
D
Lyman
SD
Williams
DE
Effect of murine mast cell growth factor (c-kit proto-oncogene ligand) on colony formation by human marrow hematopoietic progenitor cells.
Blood
77
1991
2142
37
Lemoli
R
Gulati
S
Effect of stem cell factor (c-kit ligand), granulocyte-macrophage colony stimulating factor and interleukin-3 on hematopoietic progenitors in human long-term bone marrow cultures.
Stem Cells
11
1993
435
38
van der Sluijs
J
van den Bos
C
Baert
M
van Beurden
C
Ploemacher
R
Loss of long-term repopulating ability in long-term bone marrow culture.
Leukemia
7
1993
725
39
Peters
S
Kittler
E
Ramshaw
H
Quesenberry
P
Ex vivo expansion of murine marrow cells with interleukin-3 (IL-3), IL-6, IL-11, and stem cell factor leads to impaired engraftment in irradiated hosts.
Blood
87
1996
30
40
Neben
S
Donaldson
D
Sieff
C
Mauch
P
Bodine
D
Ferrara
J
Yetz-Aldape
J
Turner
K
Synergistic Effects of interleukin-11 with other growth factors on the expansion of murine hematopoietic progenitors and maintenance of stem cells in liquid culture.
Exp Hematol
22
1994
353
41
Crawford
J
Ozer
H
Stoller
R
Johnson
D
Lyman
G
Tabbara
I
Kris
M
Grous
J
Picozzi
V
Rausch
G
Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
N Engl J Med
325
1991
164
42
Neben
S
Marcus
K
Mauch
P
Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor.
Blood
81
1993
1960
43
Harrison
D
Zsebo
K
Astle
C
Splenic primitive hematopoietic stem cell (PHSC) activity is enhanced by Steel factor because of PHSC proliferation.
Blood
83
1994
3146
44
Bodine
D
Seidel
N
Orlic
D
Bone marrow collected 14 days after in vivo administration of granulocyte colony-stimulating factor and stem cell factor to mice has 10 fold more repopulating ability than untreated bone marrow.
Blood
88
1996
89
45
Down
J
Ploemacher
R
Transient and permanent engraftment potential of murine hemopoietic stem cell subsets: Differential effects of host conditioning with gamma radiation and cytotoxic drugs.
Exp Hematol
21
1993
913
46
Hodgson
GS
Bradley
TR
Properties of haematopoietic stem cells surviving 5-fluorouracil treatment: Evidence for a pre-CFU-S cell?
Nature
281
1979
381
47
Van Zant
G
Studies of hematopoietic stem cells spared by 5-fluorouracil.
J Exp Med
159
1984
679
48
Lerner
C
Harrison
D
5-Fluorouracil spares hemopoietic stem cells responsible for long-term repopulation.
Exp Hematol
18
1990
114
49
Jones
R
Wagner
J
Celano
P
Zicha
M
Sharkis
S
Separation of pluripotent hematopoietic stem cells from spleen colony-forming cells.
Nature
347
1990
188
50
Ploemacher
R
van der Loo
J
Van Beurden
C
Baert
M
Wheat germ agglutinin affinity of murine hemopoietic stem cell subpopulations is an inverse function of their long-term repopulating ability in vitro and in vivo.
Leukemia
7
1993
120
51
Brecher
G
Ansell
J
Micklem
H
Tjio
J
Cronkite
E
Special proliferative sites are not needed for seeding and proliferation of transfused bone marrow cells in normal syngeneic mice.
Proc Natl Acad Sci USA
79
1982
5085
52
Saxe
DF
Boggs
SS
Boggs
DR
Transplantation of chromosomally marked syngeneic marrow cells into mice not subjected to hematopoietic stem cell depletion.
Exp Hematol
12
1984
277
53
Wu
D
Keating
A
Hematopoietic stem cells engraft in untreated transplant recipients.
Exp Hematol
21
1993
251
54
Kume
A
Dinauer
M
Retrovirus-mediated reconstitution of respiratory burst activity in X-linked chronic granulomatous disease cells.
Blood
84
1994
3311
Sign in via your Institution